Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Viking Therapeutics, spanning the last three ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 70% ownership.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Key Points CRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential ...

Detailed price information for Thermo Fisher Scientific Inc (TMO-N) from The Globe and Mail including charting and trades.